Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17347
ชื่อเรื่อง: Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study
ผู้แต่ง: Kanokrungsee S.
Pruettivorawongse D.
Rajatanavin N.
Keywords: bimatoprost
tacrolimus
bimatoprost
tacrolimus
adult
Article
body mass
burning sensation
clinical article
clinical assessment tool
clinical outcome
controlled study
digital imaging
disease duration
drug efficacy
drug safety
face disorder
family history
female
human
hyperthyroidism
hypertrichosis
image analysis
intraocular pressure
male
middle aged
nonsegmental facial vitiligo
patient
photography
pruritus
randomized controlled trial
side effect
single blind procedure
skin examination
skin pigmentation
skin repigmentation
surface area
Thailand
treatment duration
vitiligo
Vitiligo Disease Activity Score
vitiligo surface area
face
treatment outcome
vitiligo
Bimatoprost
Face
Humans
Tacrolimus
Treatment Outcome
Vitiligo
วันที่เผยแพร่: 2021
บทคัดย่อ: Background: Vitiligo is a common acquired pigmentary disorder. Bimatoprost ophthalmic solution was indicated in the treatment of open-angle glaucoma and eyebrow hypotrichosis. However, lid hyperpigmentation was reported as a complication. Objective: To study the efficacy and safety of 0.01% bimatoprost solution compared with 0.1% tacrolimus ointment in patients with nonsegmental facial vitiligo. Methods: Patients with more than 2 vitiliginous patches on the face were enrolled. Vitiliginous patches were randomized to receive topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution, applied twice daily for 12 weeks. The vitiligo surface area (VSA, cm2) was calculated, and the percentage of repigmentation was assessed. Results: Ten patients completed the study. At the baseline, the mean VSA was comparable between the two groups. By week 12, the VSA decreased at a statistically significant level among both groups compared to the baseline (P <.05). However, there was not a statistically significant difference between both groups. In terms of repigmentation at week 12, 20% of the patients in the bimatoprost group and 10% in the tacrolimus group achieved >50% repigmentation; the overall grading score between two groups were not different at a statistically significant level. The side effects of bimatoprost were reported as itching and burning. There were no changes in intraocular pressure in 2 patients who had lid involvement. Conclusion: Topical bimatoprost solutions were safe and effective for the treatment of nonsegmental facial vitiligo with comparable results to tacrolimus ointment. It can be considered as an alternative treatment for facial vitiligo. © 2020 Wiley Periodicals LLC
URI: https://ir.swu.ac.th/jspui/handle/123456789/17347
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089557074&doi=10.1111%2fjocd.13648&partnerID=40&md5=97db1483475cfb60b7bdb90f8a124c87
ISSN: 14732130
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.